Efalex — Competitive Intelligence Brief

Efalex (DOCONEXENT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin C [EPC]. Area: Metabolic.

marketed Vitamin C [EPC] Free fatty acid receptor 1 Metabolic Small molecule

Target snapshot

Efalex (DOCONEXENT).

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Efalex TARGET	DOCONEXENT		marketed	Vitamin C [EPC]	Free fatty acid receptor 1
Gamolenic	GAMOLENIC ACID		marketed	gamolenic acid	Free fatty acid receptor 1, Peroxisome proliferator-activated receptor delta, 3-oxo-5-alpha-steroid 4-dehydrogenase 2
Linolenate	linolenic acid		marketed	linolenic acid	Fatty acid-binding protein, heart, Free fatty acid receptor 1, Peroxisome proliferator-activated receptor delta
Lauric Acid	dodecanoic acid		marketed	dodecanoic acid	G-protein coupled receptor 84, Free fatty acid receptor 1, Peroxisome proliferator-activated receptor delta
Infuvite Adult	alpha-tocopherol acetate	Novartis	marketed	Vitamin C [EPC]		2000-01-01
Glucoferron	FERROUS GLUCONATE	Sanofi	marketed	Vitamin C [EPC]		1999-01-01
Pyridoxine Hydrochloride	PYRIDOXINE	Pfizer	marketed	Vitamin C [EPC]	Cystathionine beta-synthase	1993-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin C [EPC] class)

1. · 16 drugs in this class
2. Pfizer · 5 drugs in this class
3. Energique, Inc. · 2 drugs in this class
4. Exela Pharma · 1 drug in this class
5. Faculdade de Medicina do ABC · 1 drug in this class
6. Glaukos · 1 drug in this class
7. Hippocration General Hospital · 1 drug in this class
8. Jun Gong, MD · 1 drug in this class
9. MEDPOINTE PHARM HLC · 1 drug in this class
10. Novartis · 1 drug in this class